Lung Cancer
News
FDA approves lorlatinib as second line for ALK-positive advanced NSCLC
The approval was based on an overall response rate of 48% in patients previously treated with one or more ALK kinase inhibitors.
News
FDA expands approval of pembrolizumab in NSCLC
Pembrolizumab is now approved for use in combination with carboplatin and either paclitaxel or nab-paclitaxel for the first-line treatment of...
Conference Coverage
Checkpoint inhibitor seems safe and effective for patients with HIV
MUNICH – No immune-related adverse events or deaths due to drug toxicity occurred in cancer patients with HIV treated with nivolumab.
Conference Coverage
PCI safely improves iPFS and OS in advanced NSCLC
TORONTO –
Conference Coverage
Neoadjuvant TKI for advanced NSCLC falls short
MUNICH – Erlotinib for stage IIIA (N2) NSCLC may increase progression-free survival, but clinical benefits fall...
Conference Coverage
DETERRED trial: Concurrent atezolizumab, CRT shows promise in LA-NSCLC
TORONTO – Concurrent atezolizumab and chemoradiation therapy is safe and showed promising efficacy in LA-NSCLC in...
Conference Coverage
ALTA-1L: Brigatinib beats crizotinib for PFS in ALK-positive NSCLC
The ALTA-1L trial showed a 51% reduction in progression-free survival with brigatinib versus crizotinib in ALK-positive NSCLC.
From the Journals
Epacadostat plus pembrolizumab shows promise in advanced solid tumors
Investigational drug epacadostat plus pembrolizumab demonstrated promising antitumor activity and safety in patients with advanced solid tumors....
Conference Coverage
IMPower132 trial: Atezolizumab improves PFS in advanced nonsquamous NSCLC
TORONTO – Atezolizumab as part of first-line and maintenance therapy improves PFS in advanced nonsquamous NSCLC.
Conference Coverage
IMpower133: Atezolizumab plus standard chemotherapy boosted survival in ES-SCLC
Adding atezolizumab to standard first-line ES-SCLC treatment significantly improved overall survival and progression-free survival in the...
From the Journals
ALEX: Alectinib showed superior CNS efficacy in ALK+ NSCLC
Time to CNS progression was significantly longer with alectinib versus crizotinib.